Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on ATAI Life Sciences (ATAI – Research Report). The associated ...

Atai Life Sciences (NASDAQ:ATAI) reported positive topline results from a Phase 2a study of the psychedelic drug BPL-003 in the treatment of patients with moderate to severe alcohol use disorder, or ...

Life Sciences (ATAI) announced topline results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in 12 patients with moderate to ...

Atai reported “dose-dependent and robust subjective effects” at these higher doses, with 13 out of 14 participants scoring greater than 7 out of 10 on the Subjective Intensity Rating Scale at ...

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinical development of short ...

(RTTNews) - Biopharmaceutical company atai Life Sciences N.V. (ATAI) announced Friday key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand ...

“These drugs were undoubtedly important for patients and meaningfully advanced the treatment of major depressive disorder,” said Srinivas Rao, co-founder and chief scientific officer of atai.